Forced expression of the cyclin-dependent kinase inhibitor gene p21^cip1^in the synovial tissues was effective in treating animal models of rheumatoid arthritis (RA). Synovial hyperplasia in the treated joints was suppressed, reflecting the inhibitory effect of p21^cip1^on cell-cycle progression. Additionally, lymphocyte infiltration, expression of inflammatory cytokines, and destruction of the bone and cartilage were inhibited. To determine why the cell-cycle regulator gene exerted such anti-inflammatory effects, we investigated gene expression by rheumatoid synovial fibroblasts with or without the p21^cip1^gene transferred. We have found that p21^cip1^gene transfer downregulates the expression of various inflammatory mediators and tissue-degrading proteinases that are critically involved in the pathology of RA. These molecules included IL-6, IL-8, type I IL-1 receptor (IL-1R1), monocyte chemoattractant protein-1, macrophage inflammatory protein-3a, cathepsins B and K, and matrix metalloproteinase-1 and matrix metalloproteinase-3. Downregulation of IL-1R1 by p21^cip1^resulted in attenuated responsiveness to IL-1. Inhibition of the inflammatory gene expression by p21^cip1^was seen even when IL-1 is absent. This IL-1R1-independent suppression was accompanied by reduced activity of c-Jun N-terminal kinase, which was associated with p21^cip1^, and by inactivation of NF-κB and AP-1. These multiple regulatory effects should work in concert with the primary effect of inhibiting the cell cycle in ameliorating the arthritis, and suggest a heretofore unexplored relationship between cyclin-dependent kinase inhibitors and inflammatory molecules.
